NO791557L - Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodet - Google Patents

Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodet

Info

Publication number: NO791557L
Authority: NO; Norway
Prior art keywords: phenylalanine; blood; preparation; enzyme; preparing
Prior art date: 1978-05-12

Application number

NO791557A

Other languages

English (en)

Norwegian (no)

Inventor

Walter Marconi

Francesco Bartoli

Roberto Gianna

Franco Morisi

Giuseppina Spotorno

Original Assignee

Snam Progetti

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-05-12

Filing date

1979-05-09

Publication date

1979-11-13

1979-05-09 Application filed by Snam Progetti filed Critical Snam Progetti

1979-11-13 Publication of NO791557L publication Critical patent/NO791557L/no

Links

COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 title claims description 31
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 title claims description 31
239000008280 blood Substances 0.000 title claims description 17
210000004369 blood Anatomy 0.000 title claims description 17
238000000034 method Methods 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title claims description 6
239000000835 fiber Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 4
108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims description 3
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 9
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 6
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
201000011252 Phenylketonuria Diseases 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000001903 2-oxo-3-phenylpropanoic acid Substances 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
DEDGUGJNLNLJSR-UHFFFAOYSA-N alpha-hydroxycinnamic acid Natural products OC(=O)C(O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 3
150000003943 catecholamines Chemical class 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
229920002284 Cellulose triacetate Polymers 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
108010009736 Protein Hydrolysates Proteins 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
UUCMDZWCRNZCOY-UHFFFAOYSA-N ditazole Chemical compound O1C(N(CCO)CCO)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UUCMDZWCRNZCOY-UHFFFAOYSA-N 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 2
239000000049 pigment Substances 0.000 description 2
239000003531 protein hydrolysate Substances 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
238000009987 spinning Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001635 urinary tract Anatomy 0.000 description 2
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 description 1
RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
229940000681 5-hydroxytryptophan Drugs 0.000 description 1
102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
208000027205 Congenital disease Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
241000223253 Rhodotorula glutinis Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000003425 Tyrosinase Human genes 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
235000018823 dietary intake Nutrition 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
229960005219 gentisic acid Drugs 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
239000003617 indole-3-acetic acid Substances 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000002969 morbid Effects 0.000 description 1
239000000712 neurohormone Substances 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000003279 phenylacetic acid Substances 0.000 description 1
229960003424 phenylacetic acid Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005891 transamination reaction Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Biochemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Anesthesiology (AREA)
Nutrition Science (AREA)
Microbiology (AREA)
Dispersion Chemistry (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Cardiology (AREA)
Biotechnology (AREA)
Obesity (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Enzymes And Modification Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
External Artificial Organs (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO791557A 1978-05-12 1979-05-09 Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodet NO791557L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT23336/78A IT1096208B (it)	1978-05-12	1978-05-12	Composizione adatta alla riduzione del tenore di fenilalanina e metodo impiegante la stessa

Publications (1)

Publication Number	Publication Date
NO791557L true NO791557L (no)	1979-11-13

Family

ID=11206197

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO791557A NO791557L (no)	1978-05-12	1979-05-09	Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodet

Country Status (19)

Country	Link
US (1)	US4248704A (cs)
JP (1)	JPS54147909A (cs)
AU (1)	AU521742B2 (cs)
BE (1)	BE876204A (cs)
CA (1)	CA1130206A (cs)
CS (1)	CS214795B2 (cs)
DD (1)	DD143730A5 (cs)
DE (1)	DE2919127C2 (cs)
DK (1)	DK182479A (cs)
FR (1)	FR2425246A1 (cs)
GB (1)	GB2020668B (cs)
HU (1)	HU181954B (cs)
IL (1)	IL57251A (cs)
IT (1)	IT1096208B (cs)
LU (1)	LU81242A1 (cs)
NL (1)	NL7903789A (cs)
NO (1)	NO791557L (cs)
SE (1)	SE7904161L (cs)
ZA (1)	ZA792249B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU194487B (en) *	1979-12-28	1988-02-29	Chinoin Gyogyszer Es Vegyeszet	Process for producing food-preparation suitable for feeding sicks of phenylketoneurea from protein hydrolysates
EP0034304B1 (en) *	1980-02-13	1984-11-07	SORIN BIOMEDICA S.p.A.	Method of immobilizing an enzyme in a bundle of cellulosic fibres for a fibre-bundle dialyzer for purifying blood
JPS56145857A (en) *	1980-04-15	1981-11-12	Unitika Ltd	Material for purifying body fluid and its manufacture
US4562151A (en) *	1983-09-06	1985-12-31	Monsanto Company	Stabilization of L-phenylalanine ammonia-lyase enzyme
JPS61353A (ja) *	1984-06-13	1986-01-06	テルモ株式会社	薬剤投与装置
JPH0655223B2 (ja) *	1986-05-06	1994-07-27	宇部興産株式会社	非生物学的吸着剤
US4955857A (en) *	1988-07-18	1990-09-11	Shettigar Udipi R	Multi-enzyme bioreactor therapy for cancer
US5324253A (en) *	1992-03-02	1994-06-28	Mcrea James C	Cannula apparatus and system for heparin removal from blood
DK75593D0 (cs) *	1993-06-25	1993-06-25	Novo Nordisk As
DE69427745T2 (de) *	1993-08-10	2002-05-23	Slobodan Tepic	Gerät zum behandeln von tumoren mittels selektiver proteinverringerung
US5868936A (en) *	1996-06-20	1999-02-09	Baxter International Inc.	Affinity membrane system and method of using same
CN116114787A (zh) *	2023-03-16	2023-05-16	中国农业科学院农产品加工研究所	一种高效脱除蛋白原料中苯丙氨酸的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL128859C (cs) *	1960-09-19
US3441142A (en) *	1966-07-21	1969-04-29	Dow Chemical Co	Nonthrombogenic plastic membranes
US3522346A (en) *	1968-05-31	1970-07-28	Research Corp	Nonthrombogenic microcapsules
IL32406A (en) *	1968-06-26	1973-01-30	Snam Progetti	Enzyme preparations comprising a solution or dispersion of enzyme occluded in filaments of cellulose esters or synthetic polymers
US3673612A (en) *	1970-08-28	1972-07-04	Massachusetts Inst Technology	Non-thrombogenic materials and methods for their preparation
US3809613A (en) *	1971-05-28	1974-05-07	Research Corp	Biocatalytic module
JPS5136810B2 (cs) *	1972-08-04	1976-10-12
US4004980A (en) *	1975-03-25	1977-01-25	Purdue Research Foundation	Enzyme entrappment with cellulose acetate formulations
US4051040A (en) *	1976-03-17	1977-09-27	John L. Hutchinson	Antithrombogenic hemo dialysis membranes
JPS5340691A (en) *	1976-04-01	1978-04-13	Korufu Fuaundeeshiyon Za	Method and apparatus for removing impurities from fluids
IT1085524B (it) *	1977-03-22	1985-05-28	Snam Progetti	Materiali e fibre porose biocompatibili in grado di inglobare sostanze di interesse biologico e metodi per il loro ottenimento

1978
- 1978-05-12 IT IT23336/78A patent/IT1096208B/it active
1979
- 1979-05-03 DK DK182579A patent/DK182479A/da unknown
- 1979-05-03 US US06/035,528 patent/US4248704A/en not_active Expired - Lifetime
- 1979-05-09 AU AU46895/79A patent/AU521742B2/en not_active Ceased
- 1979-05-09 GB GB7916059A patent/GB2020668B/en not_active Expired
- 1979-05-09 NO NO791557A patent/NO791557L/no unknown
- 1979-05-09 ZA ZA792249A patent/ZA792249B/xx unknown
- 1979-05-10 LU LU81242A patent/LU81242A1/xx unknown
- 1979-05-10 FR FR7911923A patent/FR2425246A1/fr active Granted
- 1979-05-10 DD DD79212783A patent/DD143730A5/de unknown
- 1979-05-11 BE BE0/195119A patent/BE876204A/xx not_active IP Right Cessation
- 1979-05-11 CA CA327,577A patent/CA1130206A/en not_active Expired
- 1979-05-11 IL IL57251A patent/IL57251A/xx unknown
- 1979-05-11 JP JP5718979A patent/JPS54147909A/ja active Pending
- 1979-05-11 HU HU79SA3181A patent/HU181954B/hu unknown
- 1979-05-11 SE SE7904161A patent/SE7904161L/ not_active Application Discontinuation
- 1979-05-11 DE DE2919127A patent/DE2919127C2/de not_active Expired
- 1979-05-12 CS CS793256A patent/CS214795B2/cs unknown
- 1979-05-14 NL NL7903789A patent/NL7903789A/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
HU181954B (en)	1983-11-28
ZA792249B (en)	1980-05-28
IT7823336A0 (it)	1978-05-12
LU81242A1 (fr)	1979-09-10
DE2919127A1 (de)	1979-11-22
DE2919127C2 (de)	1982-10-21
JPS54147909A (en)	1979-11-19
AU4689579A (en)	1979-11-15
BE876204A (fr)	1979-11-12
SE7904161L (sv)	1979-11-13
GB2020668A (en)	1979-11-21
CS214795B2 (en)	1982-05-28
CA1130206A (en)	1982-08-24
AU521742B2 (en)	1982-04-29
GB2020668B (en)	1982-09-08
IL57251A0 (en)	1979-09-30
IL57251A (en)	1982-04-30
DD143730A5 (de)	1980-09-10
US4248704A (en)	1981-02-03
IT1096208B (it)	1985-08-26
FR2425246B1 (cs)	1983-08-05
FR2425246A1 (fr)	1979-12-07
DK182479A (da)	1979-11-13
NL7903789A (nl)	1979-11-14

Publication	Publication Date	Title
Eriksson et al.	1998	Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis
AU701724B2 (en)	1999-02-04	Biochemically balanced peritoneal dialysis solutions
NO791557L (no)	1979-11-13	Fremgangsmaate for fremstilling av et preparat for aa redusere fenylalanininnholdet i blodet
Abbott et al.	1984	Extracellular metabolism of glutathione accounts for its disappearance from the basolateral circulation of the kidney.
FR2501692A1 (fr)	1982-09-17	Nouveau produit d'erythropoietine et procede pour sa preparation
JPH08508300A (ja)	1996-09-03	マルトデキストリン及びアミノ酸を含有する腹膜透析液
Nagase et al.	1985	Biosynthesis of methylguanidine in isolated rat hepatocytes and in vivo
Broyer et al.	1983	Nutritional and metabolic studies in children on continuous ambulatory peritoneal dialysis.
JPH11502875A (ja)	1999-03-09	臨床用のマイクロカプセル封入遺伝子操作微生物
NZ211101A (en)	1988-04-29	Glucose polymer containing compositions for use in peritoneal dialysis
Galim et al.	1980	Branched-chain Amino Acid Nitrogen Transfer to Alanine In Vivo in Dogs: DIRECT ISOTOPIC DETERMINATION WITH [15 N] LEUCINE
Owen et al.	1961	The effect of induced hyperammonemia on renal ammonia metabolism
Stier et al.	1984	Serotonin formation in nonblood-perfused rat kidneys.
JPS6042207B2 (ja)	1985-09-20	胎盤よりプラスミノ−ゲン型活性化合物を抽出する方法
Weinberg et al.	1977	Racemization and amination of the keto-analog of isoleucine in the intact dog
Pagliassotti et al.	1997	Increased net hepatic glucose output from gluconeogenic precursors after high-sucrose diet feeding in male rats
Bories et al.	1982	Lecithin: cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients
Borland et al.	1987	Serum oxalate in chronic renal failure
Ratge et al.	1991	Distribution of free and conjugated catecholamines between plasma, platelets and erythrocytes: different effects of intravenous and oral catecholamine administrations.
CN116178494B (zh)	2025-04-25	一种解酒多肽
AU598721B2 (en)	1990-07-05	Method of lowering blood sugar level in vertebrates
El Sayed et al.	1990	Differential effects of amino acids on the isolated perfused rat kidney
Mabuchi et al.	1988	A major endogenous ligand substance involved in renal failure
Yokozawa et al.	1997	In vivo effect of hydroxyl radical scavenger on methylguanidine production from creatinine
Edman et al.	1983	Use of immobilized L-asparaginase in acrylic microparticles in an extracorporeal hollow-fiber dialyzer.